Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220181 | 1.00 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8209360 | 1.00 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8218868 | 1.00 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8216992 | 1.00 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8220850 | 0.97 | CES2 (0.42) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8215682 | 0.95 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8216045 | 0.95 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8208486 | 0.95 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8217336 | 0.95 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL8218470 | 0.95 | CES2 (0.44) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627656-B2 | Antagonists of the pain and inflammatory effects of E-type prostaglandins administered alone or in combination with analgesics, antipyretics, NSAIDs, antitussives, decongestants etc | MERCK FROSST CANADA LTD. (CA) | 2003-09-30 | — | — | US | disclosed |
| EP-1278734-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | Merck Frosst Canada & Co. (CA) | 2003-01-29 | — | — | EP | disclosed |
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | MERCK FROSST CANADA LTD. (CA) | 2002-06-27 | — | — | US | disclosed |
| WO-2001081312-A2 | METHOD OF TREATMENT USING PHENYL AND BIARYL DERIVATIVES AS PROSTAGLANDIN E INHIBITORS AND COMPOUNDS USEFUL THEREFORE | MERCK FROSST CANADA & CO. (CA) | 2001-11-01 | — | — | WO | disclosed |
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| US-6277839-B1 | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2001-08-21 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119555-A1 | BIPHENYLENE LACTAMS AS PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA INC. (CA) | 2001-08-01 | — | — | EP | disclosed |
| US-6211197-B1 | CARBOXYLIC ACID OR TETRAZOLE DERIVATES; ANALGESICS, ANTIPYRETICS, AND ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2001-04-03 | — | — | US | disclosed |
| US-6143198-A | SUITABLE FOR USE AS ELECTRO-OPTICAL DISPLAY MATERIALS; LIQUID CRYSTALLINE COMPOUND HAVING A LARGE ELASTIC CONSTANT RATIO, EXCELLENT COMPATIBILITY WITH OTHER LIQUID CRYSTALLINE COMPOUND, AND LOW TEMPERATURE CHEMICAL STABILITY | CHISSO CORPORATION (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0639181-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-02-22 | — | — | EP | disclosed |
| WO-1994027968-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-12-08 | — | — | WO | disclosed |
| US-5360815-A | Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1994-11-01 | — | — | US | disclosed |
| US-5350760-A | Aza-5,5-fused hetrocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1994-09-27 | — | — | US | disclosed |
| WO-1994014815-A1 | DIARYL 5,6-FUSEDHETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604114-A1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993021169-A1 | BENZOTHIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021168-A1 | THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| US-5036067-A | Enzyme inhibotors | MERCK & CO., INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | CES2 2822/4885CES1 2081/4885GPR84 83/4885 |
| US-20020082266-A1 | Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore | PTGER1, PTGS1, PTGES | CES2 983/4885CES1 74/4885GPR84 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.